- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
- Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech streymir kynningu fyrir fjárfesta 3. apríl 2024 kl. 12:15 að íslenskum tíma
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
- Alvotech Announces Increase in Number of Own Shares
- Alvotech tilkynnir um útgáfu eigin hlutabréfa
- Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
- Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
More ▼
Key statistics
On Monday, Alvotech SA (Z45:DEU) closed at 12.60, -27.17% below its 52-week high of 17.30, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.55 |
---|---|
High | 13.10 |
Low | 11.60 |
Bid | 12.35 |
Offer | 12.65 |
Previous close | 12.50 |
Average volume | 198.90 |
---|---|
Shares outstanding | 266.82m |
Free float | 72.67m |
P/E (TTM) | -- |
Market cap | 3.56bn USD |
EPS (TTM) | -2.40 USD |
Data delayed at least 15 minutes, as of Apr 22 2024.
More ▼